AnaptysBio Posts Q2 Profit on $181.5M Tax Benefit Tied to First Tracks Separation

AnaptysBio Inc. (ANAB) swung to a profit in the second quarter of 2026, driven primarily by a $181.5 million tax benefit recognized after its separation from First Tracks Biotherapeutics, the clinical-stage biotechnology company reported on Sept. 22, 2026. Collaboration revenue also rose in the quarter, lifted by higher payments under existing agreements, though the company did not disclose the precise figure in its preliminary statement. The tax benefit, tied to the corporate separation, was the key factor behind the earnings turnaround and does not reflect a comparable improvement in ongoing operations.